Soranib

Sorafenib is an oral, small molecule targeted anticancer medicine classified as a multikinase inhibitor. It is widely used in oncology for the management of certain advanced cancers, particularly hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine therapy. This works by targeting multiple intracellular and cell surface kinases involved in tumor cell proliferation and angiogenesis, helping to slow cancer progression.
The mechanism of action of Sorafenib involves inhibition of several key signaling pathways. It blocks RAF kinases, which play an important role in the MAPK/ERK pathway responsible for tumor cell growth. In addition, it inhibits vascular endothelial growth factor receptors (VEGFR 2 and VEGFR 3) and platelet derived growth factor receptor (PDGFR β), reducing tumor blood vessel formation. By simultaneously targeting tumor growth and angiogenesis, It helps control disease progression in advanced malignancies.
Sorafenib is administered orally, usually twice daily, and should be taken on an empty stomach or with a low fat meal for optimal absorption. Treatment duration depends on the patient’s response and tolerance. Dose adjustments may be required based on side effects, liver function, or overall clinical condition. Regular monitoring by healthcare professionals is essential during therapy.
Common side effects associated with Sorafenib include hand foot skin reaction, diarrhea, fatigue, hypertension, rash, hair thinning, and nausea. More serious but less frequent adverse effects may include cardiac events, bleeding, and liver dysfunction. Patients are advised to report any unusual symptoms promptly.
Overall, Sorafenib has become an important targeted therapy in modern oncology. Its multi pathway inhibition offers a valuable treatment option for patients with advanced cancers, helping to improve disease control and extend progression free survival when used under proper medical supervision.